Charlotte Jeanneau | Drug Delivery | Best Researcher Award

Published on by Applied Scientist

Best Researcher Award

Charlotte Jeanneau
Université de Tours

Charlotte Jeanneau
Affiliation Université de Tours
Country France
Scopus ID 6701451744
Documents 56
Citations 3,238
h-index 27
Subject Area Drug Delivery
Event Applied Scientist Awards

Charlotte Jeanneau is a researcher affiliated with Université de Tours whose documented research profile is associated with the field of Drug Delivery. The supplied bibliometric record identifies 56 documents, 3,238 citations, and an h-index of 27 under Scopus Author ID 6701451744. These indicators provide a quantitative view of indexed research activity and citation impact, while the scope and significance of individual contributions require consideration of the underlying publications and their scientific context.[1]

Abstract

This article presents an academic recognition profile for Charlotte Jeanneau, affiliated with Université de Tours and associated with the research area of Drug Delivery. The supplied Scopus information records 56 documents, 3,238 citations, and an h-index of 27. Such bibliometric measures are commonly used to describe aspects of scholarly productivity and citation visibility, although they should be interpreted alongside publication quality, research relevance, methodological contribution, collaboration, and broader scientific influence.[1] Drug delivery research encompasses the development and evaluation of approaches intended to transport therapeutic agents to appropriate biological sites while addressing issues such as stability, bioavailability, targeting, controlled release, and safety.[2]

Keywords

Drug Delivery; Pharmaceutical Sciences; Therapeutic Delivery Systems; Drug Delivery Technologies; Nanomedicine; Research Impact; Biomedical Research

Introduction

Drug delivery is an interdisciplinary research area connecting pharmaceutical science, chemistry, materials science, biology, medicine, and engineering. Modern drug delivery systems seek to improve how therapeutic compounds are administered, distributed, released, and made available at their intended biological targets. Research in this field includes conventional formulation approaches as well as advanced carriers, controlled-release systems, nanostructured platforms, and targeted delivery strategies.[2][4]

Research Profile

The supplied academic information identifies Charlotte Jeanneau with Université de Tours and the subject area of Drug Delivery. The Scopus identifier associated with the profile is 6701451744. According to the supplied bibliometric record, the profile contains 56 indexed documents, 3,238 citations, and an h-index of 27.[1][2]

Research Contributions

The research area associated with this profile, Drug Delivery, addresses the scientific challenge of delivering therapeutic substances with appropriate spatial and temporal control. Important research directions in the discipline include improving drug solubility and stability, regulating release kinetics, developing carrier systems, enhancing biological availability, and reducing unintended exposure. Contemporary approaches also examine how physicochemical properties of delivery materials influence biological interactions and therapeutic performance.[5][3] Lipid nanoparticles represent another important delivery technology, particularly in the development of nucleic-acid-based therapeutics and related biomedical applications.[4]

Publications

The supplied Scopus record reports 56 documents for the researcher profile identified by Author ID 6701451744.[1] A complete publication-level assessment would require examination of the individual indexed records, including article titles, journals, publication years, author contributions, citation distributions, and subject classifications. Because those individual publication records were not supplied as part of the input data, this profile does not attribute specific publications to Charlotte Jeanneau beyond the provided aggregate Scopus information.[4]

Research Impact

The supplied bibliometric indicators report 3,238 citations and an h-index of 27 across 56 documents in the identified Scopus profile.[1] Citation counts can provide evidence of how frequently indexed publications have been cited within the scholarly literature, while the h-index combines publication and citation information into a single measure. These metrics are database-dependent and may vary with indexing coverage, author disambiguation, citation updates, and the date on which the profile is examined.

Award Suitability

The Best Researcher Award profile is based on the supplied affiliation, research subject area, and Scopus bibliometric record. The reported combination of 56 documents, 3,238 citations, and an h-index of 27 provides quantitative information that can form part of an academic recognition assessment.[1] A complete award evaluation may additionally consider the originality and significance of research contributions, publication quality, scholarly leadership, collaboration, research continuity, and evidence of broader scientific or societal relevance.

Conclusion

Charlotte Jeanneau, affiliated with Université de Tours, is presented in this academic recognition profile as a researcher associated with Drug Delivery. The supplied Scopus information records 56 documents, 3,238 citations, and an h-index of 27 under Author ID 6701451744.[1] Drug Delivery is a multidisciplinary field concerned with developing scientifically controlled approaches for transporting therapeutic agents and improving their delivery characteristics.[2]

References

  1. Elsevier. (n.d.). Scopus author details: Charlotte Jeanneau, Author ID 6701451744. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=6701451744
  2. T Giraud, C Jeanneau, I About. (2026). Anti-inflammatory potential of a New Calcium Silicate based Endodontic Sealer.
    https://www.sciencedirect.com/science/article/pii/S0099239926003596
  3. C Le Fournis, T Giraud, S Roumani, C Jeanneau, I About. (2026). Macrophage‐Pulp Fibroblast Interactions Modulate Initial Dental Pulp Regeneration In Vitro.
    https://onlinelibrary.wiley.com/doi/abs/10.1111/iej.70103
  4. A Cotten, C Jeanneau, P Decherchi, I About. (2024). Complement C5a Implication in Axonal Growth After Injury.
    https://www.mdpi.com/2073-4409/13/20/1729
  5. C Jeanneau, JH Catherine, T Giraud, R Lan, I About. (2024). The Added Value of a Collagenated Thermosensitive Bone Substitute as a Scaffold for Bone Regeneration.
    https://www.mdpi.com/1996-1944/17/3/625

Jinshun Xu | Biomedical Nanotechnology | Innovative Research Award

Published on by Applied Scientist

Innovative Research Award

Jinshun Xu
Sichuan Cancer Hospital, China

Jinshun Xu
Affiliation Sichuan Cancer Hospital
Country China
Scopus ID 56666258500
Documents 57
Citations 809
h-index 15
Subject Area Biomedical Nanotechnology
Event Applied Scientist Awards
ORCID 0000-0003-2420-2320

Jinshun Xu is a Chinese physician-scientist and researcher at Sichuan Cancer Hospital whose work focuses on biomedical nanotechnology, ultrasound medicine, cancer imaging, and image-guided therapeutic interventions. His research has contributed to the development of microwave-responsive nanocarriers, ultrasound-mediated drug delivery systems, and immune-enhanced cancer therapies. These contributions reflect the type of interdisciplinary innovation and translational research recognized by the Innovative Research Award.[1]

Abstract

Jinshun Xu is a Chinese physician-scientist whose research focuses on the convergence of biomedical nanotechnology, ultrasound medicine, molecular imaging, and minimally invasive oncologic therapies. His investigations have emphasized microwave-responsive nanocarriers, ultrasound-mediated drug delivery systems, image-guided ablation strategies, and immune-enhancing therapeutic platforms. Through multidisciplinary collaborations, he has contributed to the development of advanced treatment approaches for hepatocellular carcinoma, breast cancer, prostate cancer, and other malignancies. His publication record, citation performance, and leadership of nationally and provincially funded research projects demonstrate substantial scientific productivity and translational relevance.[2]

Keywords

Biomedical Nanotechnology; Ultrasound Medicine; Cancer Imaging; Microwave Ablation; Nanocarriers; Immunotherapy; Molecular Imaging; Drug Delivery Systems; Oncology Research; Translational Medicine.

Introduction

Modern cancer research increasingly depends upon interdisciplinary approaches that integrate engineering, nanotechnology, imaging sciences, and clinical medicine. Researchers working at these interfaces play an important role in advancing precision medicine and minimally invasive therapeutic strategies. Jinshun Xu’s academic career reflects this multidisciplinary paradigm through contributions spanning ultrasound-guided interventions, microwave-responsive therapeutic systems, and nano-enabled cancer treatments.[3]

Research Profile

Jinshun Xu currently serves as Deputy Director of the Department of Ultrasound Medicine at Sichuan Cancer Hospital. His research program encompasses molecular imaging, nanomedicine, thermal ablation technologies, targeted drug delivery, ultrasound-responsive biomaterials, and cancer immunotherapy. He has led multiple competitive research projects funded by provincial foundations, university programs, and national scientific agencies, demonstrating sustained research leadership.[1]

Research Contributions

Jinshun Xu’s work involves the design of microwave-responsive nanoplatforms capable of enhancing local tumor ablation while simultaneously promoting immune activation. These systems have been investigated as strategies to improve treatment efficacy and address metastatic disease progression through combined thermal, dynamic, and immunotherapeutic mechanisms.[4]

Publications

  • Microwave ablation of benign breast tumors: a prospective study with minimum 12 months follow-up (International Journal of Hyperthermia, 2018).
  • Ultrasound-responsive nanocarriers for cancer therapy: Physiochemical features-directed design (Journal of Controlled Release, 2025).
  • Review of clinical tumor ablation advance in Asia (International Journal of Hyperthermia, 2021).
  • Phase-transitional Fe3O4/perfluorohexane microspheres for magnetic droplet vaporization (Theranostics, 2017).[5]

Research Impact

Jinshun Xu’s research is reflected in a Scopus profile reporting 57 indexed documents, more than 800 citations, and an h-index of 15. These indicators suggest consistent scholarly engagement and recognition within biomedical engineering, oncology, imaging science, and nanomedicine communities.[1]

Beyond publication metrics, his work has contributed to the advancement of translational technologies that bridge laboratory innovation and clinical implementation.[4]

Award Suitability

Jinshun Xu demonstrates characteristics commonly associated with candidates for the Innovative Research Award. These include interdisciplinary scientific contributions, leadership in externally funded research programs, development of emerging therapeutic technologies, and publication of influential work in high-impact journals. His investigations into microwave-responsive nanomedicine, ultrasound-guided interventions, and immune-enhanced cancer therapies align closely with contemporary priorities in translational biomedical research.[2][1]

Conclusion

Jinshun Xu has established a research career characterized by innovation in biomedical nanotechnology, ultrasound medicine, and image-guided cancer therapy. His contributions span fundamental nanomaterial development, translational therapeutic engineering, and clinical evaluation of advanced treatment approaches. Through a combination of scientific productivity, collaborative research leadership, and translational impact, he represents a strong candidate for recognition through the Innovative Research Award.

References

  1. Elsevier. (n.d.). Scopus author details: Jinshun Xu, Author ID 56666258500. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=56666258500
  2. Xu J., et al. (2026). Microwave-responsive nanocarrier-unlocked thermal-dynamic-immunotherapy: Rational physicochemical design-determined immunomodulation. Coordination Chemistry Reviews.
    https://doi.org/10.1016/j.ccr.2026.218126
  3. Xu J., et al. (2026). Magnetic Hyperthermia Ablation of Tumors Using Injectable Fe3O4/Calcium Phosphate Cement. ACS applied materials & interfaces
    https://pubs.acs.org/doi/abs/10.1021/acsami.5b02077
  4. Cheng X., Xu J., et al. (2024). A tumor-homing nanoframework for synergistic microwave tumor ablation and provoking strong anticancer immunity against metastasis. ACS Nano.
    https://pubs.acs.org/doi/abs/10.1021/acsnano.4c10603
  5. Xu J., Cheng X., et al. (2019). Microwave responsive nanoplatform via p-selectin mediated drug delivery for treatment of hepatocellular carcinoma with distant metastasis. Nano Letters.
    https://pubs.acs.org/doi/abs/10.1021/acs.nanolett.8b05202